Sébastien Peltier, CEO – PhD – HDR. Chairman of the Board of Directors
After completing a thesis on nutrition in the field of cardiovascular and metabolic diseases at the Laboratory of Applied and Fundamental Bioenergetics (U1055 INSERM) at Joseph Fourier University and under the direction of Prof. Xavier Leverve, Sébastien worked at a spin-off of the Université Libre de Bruxelles in Belgium, on a drug candidate in the area of enterale and parenterale nutrition. Then, in 2007, he joined the Lescuyer Laboratory and was soon responsible for managing the Research & Development Department where he notably oversaw the entire application process for one of the only health claims ever to obtain a positive response from the EFSA, for reducing a risk factor in cardiovascular diseases.
Sébastien became head of Biopôle Santé – Réseau Expert, Territoire d’Innovation, Service de valorisation en Santé (Regional Expert Network for Health Innovation and Valorization), for the Poitou-Charentes region and later for Nouvelle-Aquitaine – for over 5 years until March 2017. Sébastien also supported the Habilitation à Diriger des Recherches (HDR – Authorization to Supervise Research) program at Blaise Pascal University (which later became known as the University of Clermont Auvergne, Clermont-Ferrand), allowing him to officially supervise PhD students.
He is an active member of the French Nutrition Society, the French Cardiology Society and the American Diabetes Association.
He is author of over 35 international scientific articles and papers and has developed 5 patent families.
Member of the Board of Directors
Holder of an MBA from Panthéon Sorbonne University in Paris, graduate of the Paris IAE in Finance and with a financial analysis certificate from HEC Paris, over the last 17 years, Jocelyn has worked in various project management roles within executive management for SMEs. He has brought several structural and cross-disciplinary operational projects to completion, providing support during the creation, restructuring and development of companies, notably in the agro-food industries. For about a decade, he worked as Administrative, Logistics and General Services Manager for the Lescuyer Laboratory, and participated in the global development and structuring of the company. He also managed multi-disciplinary teams (sales administration, logistics, accounting, HR) and was responsible for approximately 20 employees.
Jocelyn provides VALBIOTIS with strategic, financial and organizational expertise as well as a broad knowledge of the healthcare market and healthcare products in particular. He manages the finance, management control, human resources and general services departments.
Jocelyn is a member of Club Finance HEC and the Institut des Hautes Finances.
Il apporte à VALBIOTIS son expertise stratégique, financière et organisationnelle, ainsi que sa connaissance du marché de la santé et en particulier des produits de santé. Il dirige les services financiers, le contrôle de gestion, les ressources humaines et les services généraux.
Jocelyn est membre du Club Finance HEC ainsi que de l’Institut des Hautes Finances.
CSO – PhD, HDR. Member of the Board of Directors
With over 10 years’ research experience, Pascal has in-depth expertise in metabolic diseases. Pascal was a lecturer at the University of Clermont Auvergne between 2008 and 2018, and has headed the establishment’s technical functional assessment platform since 2010. He has also set up several international scientific partnerships with Vanderbilt University (Nashville, USA), the Maine Medical Center Research Institute (Portland, Oregon) and the University of Texas (Houston, USA) as part of research projects on the pathophysiology of type 2 diabetes. In 2005, Pascal Sirvent obtained a PhD in Biological and Biochemical Health Sciences from the Montpellier I University and authorization to supervise research in 2016.
As a member of our Scientific Committee, Pascal was in charge of collaborative projects between the University of Clermont Auvergne and VALBIOTIS.
In 2017, he was appointed Chief Scientific Officer (CSO) at VALBIOTIS and took over management of the Discovery and Preclinical and Translational Research Department. Pascal is also at the helm of our two R&D centers in La Rochelle and Riom. Furthermore, he is the co-inventor of several key technologies used in the development of VALBIOTIS.
CMO – Member of the Board of Directors
Murielle has 25 years of experience in the healthcare sector. After managing a team responsible for creating anddeveloping clinical study management at Nantes UniversityHospital, in 2002, Murielle CAZAUBIEL founded BIOFORTIS, a now leading CRO (Contract Research Organization). In 2009, she successfully managed the integration of BIOFORTIS with the MÉRIEUX group into the subsidiary MÉRIEUX NUTRISCIENCES.
In addition, Murielle took onthe role of Chair of the «Atlanpole Biothérapies» Cluster from 2012 to 2018, in order to develop new therapies and to accelerate the development of personalized medicine, facilitating research programs between university academics and industry professionals.
Founder and CEO of Nanobiotix. Chairman of the Supervisory Board
Holder of a PHD in Physics and Chemistry, specialized in nanomaterials, from the Pierre and Marie Curie University and the CEA (French Commission for Atomic Energy), and with a Master of Advanced Studies in Condensed Matter Physics from UPVI-ESPCI (Paris), Laurent has gained extensive experience in the science and techniques associated with nanomedicine, a field in which he has worked for over a decade. His research is at the forefront of chemistry, biology and physics, and has enabled him to develop a certain number of practical applications in nanomedicine, such as the NanoXray technology that could herald the start of a new era in cancer treatment.
Before founding Nanobiotix in 2003, for several years, Laurent worked as a consultant developing nanotechnology applications for groups such as Sanofi (Pharma), Guerbet (Medical imaging), Rhodia (Chemistry), as well as for biotechnology start-ups. Author of 35 international scientific publications and papers, Laurent has filed many patents and topped off his career with a post-doctorate at the Institute for Lasers, Photonics and Biophotonics of SUNY (State University of New York), Buffalo, in the United States.
Vice-President of Global Strategic Operations, Ipsen Consumer HealthCare Division. Member of Supervisory Board
Sébastien is an expert in the field of Consumer Healthcare and Nutrition and, over the last 20 years, has held various different positions in marketing and innovation for leading pharmaceutical groups.
He has gained unique experience in consumer marketing and product innovation on a national and global level.
Sébastien previously worked as Managing Director at Biofortis Europe, a subsidiary of Mérieux Nutrisciences, Director of Global Innovation “Probiotic Platform” at Merck Consumer Healthcare, Director of Strategic Global Marketing at Merck Consumer Healthcare, Global Marketing Manager at Reckitt Benckiser, Europe Marketing Manager and Marketing Manager at Boots Healthcare International and Marketing Manager at Sanofi Aventis.
Special Scientific Adviser to the CEO, NOVARTIS Pharma SAS. Member of the Supervisory Board
Jean Zetlaoui has over 25 years’ experience in various managerial posts abroad and brings his advanced knowledge of the pharmaceutical and nutrition sectors, of their environments and their challenges.
He has been Scientific Director of NOVARTIS Pharma SAS since January 2014, is a member of the Executive Committee and was also Chief Medical Officer and member of the Nestlé Health Science Executive Committee in Vevey, Switzerland, for 2 years, contributing to the growth of personalized medicine and health nutrition-related business. Over the past 20 or so years, Jean has also held various managerial and R&D positions at SANOFI, including that of Vice-President Head of Market Access, Vice-President Head of Global Regulatory Affairs and Vice-President Deputy Head of Global Medical Affairs.
Jean is also Vice-President of the Alliance for Research and Innovation in Health Industries (ARIIS) and Chairman of the working group on the attractiveness of France for clinical research headed by Leem, an association of French pharmaceutical companies.
Before joining the pharmaceutical industry, Dr. Zetlaoui worked as a hospital practitioner at the Bicêtre University Hospital (CHU).
Jean holds a medical degree and a specialization in anesthesia and resuscitation. He has also completed an Executive MBA in Finance and International Business at the ESSEC Business School (1991).
Investment Director at CM-CIC Investissement
As a graduate of ICN Business School in Nancy, holder of a post-graduate degree in accounting (DECS) and member of the French Society of Financial Analysts (SFAF), Agnès began her career in 1986 in Banque de Vizille, specialized in mid-cap transactions, which would merge in 2011 with other entities of the Crédit Mutuel Alliance Fédérale group to create CM-CIC INVESTISSEMENT. From 1990 to 1997, she served as Financial Director and Administrator of the Lyon hotel group SHB, which would merge with ACCOR.
In 1997, she joined AVENIR TELECOM, a distributor specialized in mobile telephony, forwhom she led the initial public offering on Eurolist C in November 1998. Over the next 17 years, asAdministrative and Financial Director of the group which included 1,800 employees and €290 million in turnover in 2015, she completed a number of mergers and acquisitions and oversaw investor relations.
In 2015, she became Financial Director of transport and logistics group TRANSALLIANCE (with 3,000 employees and €600 million in turnover) operating in 7 European countries. From June 2016 to February 2018, she performed her duties as Administrative and Financial Director at IDEOL, an innovative company created in 2010 in La Ciotat (46 employees,
€4 million in turnover) and leaderin floating offshore wind power.
VALBIOTIS is guided by a Scientific and Medical Board composed of internationally renowned experts in physiology, endocrinology, diabetology, clinical development and innovative formulation.Learn more